Core Viewpoint - Sanofi Pharmaceutical (01530) experienced a decline of over 8%, specifically 8.33%, trading at HKD 29.7 with a transaction volume of HKD 495 million following the announcement of a proposed spin-off of its subsidiary, Mandi [1] Group 1: Company Announcement - On November 20, Sanofi Pharmaceutical announced its proposal to spin off its subsidiary, Mandi, for independent listing on the Hong Kong Stock Exchange [1] - The proposed spin-off is expected to be executed through a physical distribution of Mandi shares to shareholders based on their respective holdings in the company, along with a global offering of new Mandi shares [1] - Mandi International submitted its listing application to the Hong Kong Stock Exchange yesterday [1] Group 2: Ownership Structure - As of the announcement date, Mandi is beneficially owned by Sanofi Pharmaceutical (approximately 87.16%), Yingtai Management Limited (3.38%), Mandi Group Limited (2.80%), GL Wecan Investment IV L.P. (4.00%), and Alibaba Health (Hong Kong) Technology Co., Ltd. (2.65%) [1] Group 3: Mandi's Market Position - Mandi focuses on the hair health sector within the broader skin health industry and has established a leading position [1] - Mandi launched the first domestic 5% minoxidil solution under the Mandi® brand in 2001 and plans to introduce a second-generation minoxidil product, Mandi® 5% minoxidil foam, in 2024 [1]
港股异动 | 三生制药(01530)跌超8% 拟分拆蔓迪国际于联交所主板独立上市